A review of thalidomide's history and current dermatological applications

Perri, Anthony J.; Hsu, Sylvia

doi:10.5070/d35fk5w0qv

Cited by 37 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, due to its severe teratogenic effects, it was withdrawn from the market in 1961 [54]. Moving forward, however, Thalidomide's efficacy against erythema nodosum leprosum (ENL), a cutaneous form of leprosy, led to its FDA approval for this condition in 1998 [55]. Subsequently, its anti-angiogenic properties expanded its usage to treat various skin disorders, infectious diseases, immunologic and rheumatologic disorders, hematologic diseases, and several cancer types [56][57][58].…”

Section: Thalidomidementioning

confidence: 99%

A New Hope for Multiple Myeloma: Harnessing the Power of Non-Cancer Medications

Al-Odat,

Nelson,

Budak-Alpdogan

et al. 2024

Preprint

View full text Add to dashboard Cite

Multiple myeloma (MM) is a common type of cancer that unfortunately leads to a significant number of deaths each year. The majority of the reported MM cases are detected in the advanced stages, posing significant challenges for treatment. Additionally, all MM patients eventually develop resistance or experience relapse, therefore advances in treatment are needed. However, developing new anti-cancer drugs, especially for MM, requires significant financial investment and a lengthy development process. The study of drug repurposing involves exploring the potential of existing drugs for new therapeutic uses. This can significantly reduce both time and costs, which is typically a major concern for MM patients. The utilization of pre-existing non-cancer drugs for various myeloma treatments presents a highly efficient and cost-effective strategy, considering their prior preclinical and clinical development. The drugs have shown promising potential in targeting key pathways associated with MM progression and resistance. Thalidomide exemplifies the success that can be achieved through this strategy. This review delves into the current trends, the challenges faced by conventional therapies for MM, and the importance of repurposing drugs for MM. This review highlights a noncomprehensive list of conventional therapies that have potentially significant anti-myeloma properties and anti-neoplastic effects. Additionally, we offer valuable insights into the resources that can help streamline and accelerate drug repurposing efforts in the field of MM.

show abstract

Section: Thalidomidementioning

confidence: 99%

A New Hope for Multiple Myeloma: Harnessing the Power of Non-Cancer Medications

Al-Odat,

Nelson,

Budak-Alpdogan

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…The severity of side effects associated with conventional chemotherapy has prompted the development ofvariety of drug discovery approaches. [19][20][21] This review demonstrated about the history, chemical structure, current position of phthalimide derivativesand possible mechanism of action of phthalimide derivatives on the different types of receptors associated with cancer such as angiogenesis inhibitors, tumor necrosis factor-alpha (TNF-α) synthesis inducer, tryptase enzyme inhibitors, histone deacetylase (HDAC) inhibitors, proteolysis targeting chimeras (PRO-TACs) inhibitors. It also co-stimulates human T cells, including cell proliferation mainly of the cluster of differentiation 8 (CD8 +) subset, and stimulates interleukin-2 (IL-2) and interferon gamma (IFN-γ) production, which may helpful for pharmaceutical researchers to develop target specific or multi-targeted phthalimide derivaties for anticancer drug discovery.…”

Section: Introductionmentioning

confidence: 99%

“…The maintenance of solid tumours is highly dependent on revascularization and can be regulated by agents that interfere with either the stimulation or the proliferation of endothelial cells. The severity of side effects associated with conventional chemotherapy has prompted the development ofvariety of drug discovery approaches [19‐21] …”

Section: Introductionmentioning

confidence: 99%

Phthalimides Represent a Promising Scaffold for Multi‐Targeted Anticancer Agents

Matore

Banjare

Sarthi³

et al. 2023

ChemistrySelect

View full text Add to dashboard Cite

From the last two decades, phthalimide analogues received prime interest from scientists due to its potent inhibitory action on different cancer-causing receptors. A variety of anticancer drugs are coming into the market but challenges of drug resistance, toxicities, and failure in therapy still remain. Cancer is a group of complex disorders it involves multiple receptors. So there is a need of targeting multiple receptors to get desired potent anticancer drugs with minimum harmful effects. Phthalimide scaffolds fit into these criteria as it is extensively reported for the inhibition of different cancer receptors such as VEGFR, HDAC, EGFR, TNF-α, etc. The multi-targeted mechanism of phthalimide derivatives plays a major role in anticancer therapy. Due to this advantage, there is the hope of developing some novel effective multi-targeted anticancer agents. Consider structural features and pharmacological advancement of phthalimide analogues may fulfill the current need of cancer patients. In this review, we covered history, chemistry, SAR, anticancer mechanisms, and the current status of phthalimide derivatives reported till 2022. The article specifically focused on different cancer-causing receptors inhibited by phthalimide derivatives and their mechanism of action in brief. Finally, we provided the future scope and role of phthalimide derivatives in multi-targeted anticancer drug discovery.

show abstract

Thalidomide for the Treatment of Refractory Necrobiosis Lipoidica

Kukreja¹,

Petersen²

2006

Arch Dermatol

View full text Add to dashboard Cite

A review of thalidomide's history and current dermatological applications

Cited by 37 publications

References 0 publications

A New Hope for Multiple Myeloma: Harnessing the Power of Non-Cancer Medications

A New Hope for Multiple Myeloma: Harnessing the Power of Non-Cancer Medications

Phthalimides Represent a Promising Scaffold for Multi‐Targeted Anticancer Agents

Thalidomide for the Treatment of Refractory Necrobiosis Lipoidica

Contact Info

Product

Resources

About